Updates matching "Access to Biomarker Testing"

NASHVILLE, Tenn. – Advocates from the American Cancer Society Cancer Action Network (ACS CAN), the Alzheimer’s Association and the Arthritis Foundation will join together on Tuesday, February 3, to host a news conference calling on lawmakers to pass legislation that would ensure appropriate coverage of biomarker testing. The news conference

JACKSON, Miss. – Dozens of cancer patients, survivors, caregivers and advocates will come from across Mississippi to the State Capitol on Wednesday, February 4 for the American Cancer Society Cancer Action Network’s (ACS CAN) annual Cancer Action Day . They will urge state lawmakers to make cancer policy

JACKSON, Miss. – The Mississippi House passed House Bill 565 Wednesday, paving the way for increased access to biomarker testing for patients across the Magnolia State. Biomarker testing is a key tool used by physicians to identify the most effective treatments for cancer and other diseases. “In

With the 2026 legislative session now underway in Hawai’i, the American Cancer Society Cancer Action Network (ACS CAN) is leading efforts to work with lawmakers on several initiatives which include defending Medicaid and expanding access to screenings for colorectal cancer for the state’s most vulnerable communities. ACS CAN is collaborating

Ahead of Mills' State of the State address, ACS CAN Calls Attention to Medicaid, Biomarker Testing and Medical Debt

A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Massachusetts cancer survivors and caregivers urge lawmakers to support legislation that will increase access to precision medicine and patient navigation for all communities.

As the largest coalition of Nebraska patients and provider groups in years to unite on a new health policy, we are glad to see that the Nebraska legislature recognizes the importance of biomarker testing and access to precision medicine.

Expanding access to this form of precision medicine will help more people in Connecticut get the right treatment at the right time.